Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 255.38
NLNK's Cash-to-Debt is ranked higher than
55% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NLNK: 255.38 )
Ranked among companies with meaningful Cash-to-Debt only.
NLNK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.79  Med: 53.72 Max: N/A
Current: 255.38
Equity-to-Asset 0.76
NLNK's Equity-to-Asset is ranked higher than
61% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NLNK: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
NLNK' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.11  Med: 0.78 Max: 0.93
Current: 0.76
-5.11
0.93
Piotroski F-Score: 3
Altman Z-Score: 1.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -263.74
NLNK's Operating Margin % is ranked lower than
62% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NLNK: -263.74 )
Ranked among companies with meaningful Operating Margin % only.
NLNK' s Operating Margin % Range Over the Past 10 Years
Min: -2849.13  Med: -964.85 Max: 68.12
Current: -263.74
-2849.13
68.12
Net Margin % -250.90
NLNK's Net Margin % is ranked lower than
62% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. NLNK: -250.90 )
Ranked among companies with meaningful Net Margin % only.
NLNK' s Net Margin % Range Over the Past 10 Years
Min: -2852.7  Med: -966.19 Max: 55.63
Current: -250.9
-2852.7
55.63
ROE % -58.13
NLNK's ROE % is ranked lower than
62% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NLNK: -58.13 )
Ranked among companies with meaningful ROE % only.
NLNK' s ROE % Range Over the Past 10 Years
Min: -85.27  Med: -52.36 Max: 75.23
Current: -58.13
-85.27
75.23
ROA % -46.26
NLNK's ROA % is ranked lower than
62% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. NLNK: -46.26 )
Ranked among companies with meaningful ROA % only.
NLNK' s ROA % Range Over the Past 10 Years
Min: -86.63  Med: -59.94 Max: 63.63
Current: -46.26
-86.63
63.63
ROC (Joel Greenblatt) % -1122.52
NLNK's ROC (Joel Greenblatt) % is ranked lower than
63% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. NLNK: -1122.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NLNK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1122.52  Med: -386.28 Max: 1042.38
Current: -1122.52
-1122.52
1042.38
3-Year Revenue Growth Rate 206.20
NLNK's 3-Year Revenue Growth Rate is ranked higher than
98% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NLNK: 206.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NLNK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 64.15 Max: 209.3
Current: 206.2
0
209.3
3-Year EBITDA Growth Rate 34.70
NLNK's 3-Year EBITDA Growth Rate is ranked higher than
84% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. NLNK: 34.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NLNK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.1 Max: 34.7
Current: 34.7
0
34.7
3-Year EPS without NRI Growth Rate 33.70
NLNK's 3-Year EPS without NRI Growth Rate is ranked higher than
85% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NLNK: 33.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NLNK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.3 Max: 33.7
Current: 33.7
0
33.7
GuruFocus has detected 3 Warning Signs with NewLink Genetics Corp $NLNK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NLNK's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:OBSV, NAS:ABUS, NAS:PIRS, NAS:URGN, OTCPK:OXBDF, NAS:CGEN, OTCPK:SPHRY, NAS:PTGX, NAS:KMDA, NAS:STML, NYSE:ZYME, OTCPK:CLVLF, OTCPK:BCDA, NAS:AVXL, NAS:SBBP, NAS:CRVS, NAS:NVLN, NAS:NYMX, NAS:KIN, NAS:MNOV » details
Traded in other countries:4NX.Germany,
Headquarter Location:USA
NewLink Genetics Corp is a clinical stage immuno-oncology company based in US. It focuses on developing novel immunotherapeutic products for the treatment of cancer. Its portfolio contains biologic and small-molecule immuno-oncology product candidates.

NewLink Genetics is an American biotechnology company targeting immunotherapeutic products to improve treatment options for patients with cancer. The company's portfolio contains biologic and small-molecule immuno-oncology product candidates intended to treat a wide variety of oncology indications. Its products are based on the proprietary HyperAcute Cellular Immunotherapy technology, which is expected to stimulate the human immune system.

Top Ranked Articles about NewLink Genetics Corp

Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid,
NewLink Genetics to Regain Rights to GDC-0919
Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer
NewLink Genetics to Participate in Upcoming Investor Conferences
NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance
Lifshitz & Miller LLP Announces Investigation of Bingo Nation Inc., BofI Holding, Inc., Corbus Pharmaceuticals Holdings, Inc., Lion Biotechnologies, Inc., NewLink Genetics Corporation, Power Solutions International, Inc., Walter Investment Management Corp
NewLink Genetics Announces Presentation of Two Abstracts at ASCO
NewLink Genetics to Host Its First Quarter 2017 Financial Results Conference Call on May 4, 2017
Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda® (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary
NewLink Genetics Announces Presentation of Two Abstracts at AACR

Interim Phase 2 Clinical Results of IDO Pathway Inhibitor, Indoximod Selected for an Oral Presentation During the Clinical Trial Plenary Session

AMES, Iowa, March 01, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported that two abstracts on the company’s indoximod program will be presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C.
Clinical Trials Plenary Session: Abstract CT117 - Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma, to be presented during the Novel Immuno-Oncology Agent Clinical Trials session, Tuesday April 4, 2017 10:30 a.m. - 12:45 p.m. ET.

Poster Session: Abstract 4076 - A novel prodrug of indoximod with enhanced pharmacokinetic properties, to be presented during poster session PO.ET05.01 - Mechanistic Understanding of Novel Anticancer Therapies, April 4, 2017 1 p.m. - 5 p.m. ET.
The complete text of Clinical Plenary Session abstracts that have not been selected for the press program will be posted online at 4:30 p.m. ET on Friday, March 31. The text of clinical trials abstracts that have been selected for inclusion in the press program will not be posted online until the date and time of presentation. "We are honored to have been selected by the AACR review committee for the Clinical Trials Plenary Session at the upcoming AACR meeting,” said Nicholas Vahanian, M.D., President and Chief Medical Officer.  “We look forward to sharing the data from both of these abstracts.” About NewLink Genetics Corporation NewLink Genetics is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer.  For more information, please visit http://www.newlinkgenetics.com  Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties.  All statements, other than statements of historical fact, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  These forward-looking statements include, among others, statements about  results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact.  Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the year ended December 31, 2015 and other reports filed with the U.S. Securities and Exchange Commission (SEC).  The forward-looking statements in this press release represent NewLink's views as of the date of this press release. NewLink anticipates that subsequent events and developments will cause its views to change.  However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.  You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.
Investors:
Beth Kurth
LaVoieHealthScience
617-374-8800, ext. 106
[email protected]

Media:
Alison Chen
LaVoieHealthScience
617-374-8800, ext. 104
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.88
NLNK's PB Ratio is ranked higher than
78% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NLNK: 1.88 )
Ranked among companies with meaningful PB Ratio only.
NLNK' s PB Ratio Range Over the Past 10 Years
Min: 1.56  Med: 6.17 Max: 21.18
Current: 1.88
1.56
21.18
PS Ratio 6.52
NLNK's PS Ratio is ranked higher than
64% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. NLNK: 6.52 )
Ranked among companies with meaningful PS Ratio only.
NLNK' s PS Ratio Range Over the Past 10 Years
Min: 5.42  Med: 64.53 Max: 1081.4
Current: 6.52
5.42
1081.4
Current Ratio 5.12
NLNK's Current Ratio is ranked higher than
57% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NLNK: 5.12 )
Ranked among companies with meaningful Current Ratio only.
NLNK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 10.59 Max: 25.95
Current: 5.12
0.97
25.95
Quick Ratio 5.12
NLNK's Quick Ratio is ranked higher than
59% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NLNK: 5.12 )
Ranked among companies with meaningful Quick Ratio only.
NLNK' s Quick Ratio Range Over the Past 10 Years
Min: 0.97  Med: 10.59 Max: 25.95
Current: 5.12
0.97
25.95
Days Sales Outstanding 177.18
NLNK's Days Sales Outstanding is ranked lower than
87% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. NLNK: 177.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
NLNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.42  Med: 159.67 Max: 617.06
Current: 177.18
26.42
617.06

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.10
NLNK's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NLNK: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NLNK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.6  Med: -6.95 Max: 0
Current: -3.1
-23.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.59
NLNK's Price-to-Net-Cash is ranked higher than
81% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. NLNK: 2.59 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NLNK' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.5  Med: 8.44 Max: 29.76
Current: 2.59
2.5
29.76
Price-to-Net-Current-Asset-Value 1.99
NLNK's Price-to-Net-Current-Asset-Value is ranked higher than
87% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. NLNK: 1.99 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NLNK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.99  Med: 6.73 Max: 21.93
Current: 1.99
1.99
21.93
Price-to-Tangible-Book 1.88
NLNK's Price-to-Tangible-Book is ranked higher than
82% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. NLNK: 1.88 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NLNK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.88  Med: 5.96 Max: 14.64
Current: 1.88
1.88
14.64
Price-to-Median-PS-Value 0.10
NLNK's Price-to-Median-PS-Value is ranked higher than
97% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NLNK: 0.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NLNK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 1.2 Max: 10.48
Current: 0.1
0.09
10.48
Earnings Yield (Greenblatt) % -88.50
NLNK's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. NLNK: -88.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NLNK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -141.4  Med: -7.5 Max: 16.7
Current: -88.5
-141.4
16.7

More Statistics

Revenue (TTM) (Mil) $32.82
EPS (TTM) $ -2.84
Beta2.40
Short Percentage of Float20.41%
52-Week Range $5.90 - 25.17
Shares Outstanding (Mil)29.23
» More Articles for NLNK

Headlines

Articles On GuruFocus.com
Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination w Jun 23 2017 
NewLink Genetics to Regain Rights to GDC-0919 Jun 08 2017 
Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cance Jun 02 2017 
NewLink Genetics to Participate in Upcoming Investor Conferences May 08 2017 
NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance May 04 2017 
Lifshitz & Miller LLP Announces Investigation of Bingo Nation Inc., BofI Holding, Inc., Corbus Pharm May 03 2017 
NewLink Genetics Announces Presentation of Two Abstracts at ASCO Apr 21 2017 
NewLink Genetics to Host Its First Quarter 2017 Financial Results Conference Call on May 4, 2017 Apr 13 2017 
Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda Apr 04 2017 
NewLink Genetics Announces Presentation of Two Abstracts at AACR Mar 01 2017 

More From Other Websites
Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with... Jun 23 2017
These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop? Jun 21 2017
A Surprising Disappointment Derails NewLink Genetics -- What's Next? Jun 19 2017
Are Options Traders Betting on a Big Move in NewLink (NLNK) Stock? Jun 13 2017
Roche-NewLink Drug Move Shouldn't Impact Incyte, Says Analyst Jun 09 2017
Why Sina, Eldorado Gold, and NewLink Genetics Slumped Today Jun 08 2017
Stocks Pull Off Narrow Win, But These Four Soared To New Highs Jun 08 2017
Why Is NewLink Genetics Losing One-Third of Its Value Today? Jun 08 2017
NewLink Genetics Sinks After Regaining Licensing Rights for Its Cancer Treatment Jun 08 2017
Biotech Movers: NewLink, Inovio, Juno Jun 08 2017
NewLink Genetics' stock plunges as Genentech plans to returns rights cancer treatment candidate Jun 08 2017
NewLink Genetics to Regain Rights to GDC-0919 Jun 08 2017
Why Herbalife, JinkoSolar, and NewLink Genetics Slumped Today Jun 05 2017
Biotech Movers: Loxo, NewLink, BioCryst Jun 05 2017
NewLink Genetics’ Indoximod + PROVENGE® Results in Statistically Significant Improvement in... Jun 05 2017
Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast... Jun 02 2017
Cancer drug prices could double or triple thanks to this popular but unproven drug trend Jun 02 2017
Update in Lawsuit for Investors in NewLink Genetics Corp (NASDAQ: NLNK) Shares Announced by... May 30 2017
Incyte Teams Up With Dow's Merck To Trounce Roche In Cancer May 18 2017
Biotech Stocks: Is ASCO Much Ado About Nothing? May 18 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}